Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Degrader of cancer protein IDO1 prevents cancer immune suppression by cancer and offers promising strategy to support ...
Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.
Arabian Post on MSN
Breakthrough unlocks scalable helper T cell cancer therapies
Scientists have demonstrated a dependable method to generate large numbers of helper T cells from stem cells, removing a long-standing obstacle that has limited immune-based cancer treatments. The ...
Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...
Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback